A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate

British Journal of Haematology

Volumn 153, Issue 6, 2011, Pages 796-799

  Kitawaki, Toshio ^a   Kadowaki, Norimitsu ^a   Fukunaga, Keiko ^a   Kasai, Yasunari ^a   Maekawa, Taira ^a   Ohmori, Katsuyuki ^a   Kondo, Takashige ^b   Maekawa, Ryuji ^b   Takahara, Masashi ^b   Nieda, Mie ^b   Kuzushima, Kiyotaka ^c   Ishikawa, Takayuki ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b University of Tokyo   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute myeloid leukaemia; Dendritic cells; Immunotherapy; Wilms' tumour 1; Zoledronate

Indexed keywords

CYSTYLTYROSYLTHREONYLTRYPTOPHANYLASPARAGINYLGLUTAMYLMETHIONYLASPARAGINYLLEUCINE VACCINE; GAMMA INTERFERON; MESSENGER RNA; PEPTIDE VACCINE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; LETTER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

AGED; CANCER VACCINES; DENDRITIC CELLS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MALE; TREATMENT OUTCOME; WT1 PROTEINS;

EID: 79957556001     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08490.x     Document Type: Letter

References (10)

1. Dieli, F., Poccia, F., Lipp, M., Sireci, G., Caccamo, N., Di Sano, C. & Salerno, A. (2003) Differentiation of Effector/Memory Vδ2 T Cells and Migratory Routes in Lymph Nodes or Inflammatory Sites. The Journal of Experimental Medicine, 198, 391-397.
2. Fiore, F., Castella, B., Nuschak, B., Bertieri, R., Mariani, S., Bruno, B., Pantaleoni, F., Foglietta, M., Boccadoro, M. & Massaia, M. (2007) Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood, 110, 921-927.
3. Gober, H.-J., Kistowska, M., Angman, L., Jeno, P., Mori, L. & De Libero, G. (2003) Human T Cell Receptor {gamma}{delta} Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells. The Journal of Experimental Medicine, 197, 163-168.
4. Melenhorst, J.J., Scheinberg, P., Chattopadhyay, P.K., Gostick, E., Ladell, K., Roederer, M., Hensel, N.F., Douek, D.C., Barrett, A.J. & Price, D.A. (2009) High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood, 113, 2238-2244.
5. Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O.A., Oji, Y., Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S., Sasaki, A., Udaka, K., Dohy, H., Aozasa, K., Noguchi, S., Kawase, I. & Sugiyama, H. (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Science of the United States of America, 101, 13885-13890.
6. Oka, Y., Tsuboi, A., Oji, Y., Kawase, I. & Sugiyama, H. (2008) WT1 peptide vaccine for the treatment of cancer. Current Opinion in Immunology, 20, 211-220.
7. Shin, H., Blackburn, S.D., Blattman, J.N. & Wherry, E.J. (2007) Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. The Journal of Experimental Medicine, 204, 941-949.
8. Takahara, M., Miyai, M., Tomiyama, M., Mutou, M., Nicol, A.J. & Nieda, M. (2008) Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via V{gamma}9{gamma}{delta} T cell activation. Journal of Leukocyte Biology, 83, 742-754.
9. Tsuboi, A., Oka, Y., Udaka, K., Murakami, M., Masuda, T., Nakano, A., Nakajima, H., Yasukawa, M., Hiraki, A., Oji, Y., Kawakami, M., Hosen, N., Fujioka, T., Wu, F., Taniguchi, Y., Nishida, S., Asada, M., Ogawa, H., Kawase, I. & Sugiyama, H. (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunology, Immunotherapy, 51, 614-620.
10. Van Tendeloo, V.F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., Stein, B., Smits, E.L., Schroyens, W.A., Gadisseur, A.P., Vrelust, I., Jorens, P.G., Goossens, H., de Vries, I.J., Price, D.A., Oji, Y., Oka, Y., Sugiyama, H. & Berneman, Z.N. (2010) Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Science of the United States of America, 107, 13824-13829.